The limitations of HbA1c, along with the introduction of technology in the management of DM, have led to the adoption of continuous glucose monitoring (CGM) as an alternative method of evaluating glycemic control, particularly in patients with T1DM or those with T2DM using complex insulin regimens. This evidence concerns the gene INS and type 1 diabetes mellitus.